HCW Biologics Inc (HCWB)vsRegeneron Pharmaceuticals Inc (REGN)
HCWB
HCW Biologics Inc
$1.79
-13.53%
HEALTHCARE · Cap: $11.67M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 226222% more annual revenue ($14.92B vs $6.59M). REGN leads profitability with a 29.6% profit margin vs -34.7%. REGN earns a higher WallStSmart Score of 64/100 (C+).
HCWB
Hold43
out of 100
Grade: D
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HCWB.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 49.4%
Revenue surging 129081.0% year-over-year
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
The strongest argument for HCWB centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 129081.0% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
HCWB profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
HCWB carries more volatility with a beta of 1.14 — expect wider price swings.
HCWB is growing revenue faster at 129081.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 43/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a pioneering biotechnology firm focused on advancing immunotherapies and vaccine technologies to tackle critical health issues like cancer and infectious diseases. By utilizing proprietary platforms designed to optimize immune response, the company is developing a promising pipeline of clinical candidates that aim to revolutionize patient treatment. With strategic partnerships and a dedication to fulfilling unmet medical needs, HCW Biologics stands at the forefront of the biotechnology industry, representing a compelling investment opportunity amid the sector's growth.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?